Singapore, Dec. 2 -- The Japanese Foundation for Cancer Research (JFCR), NEC Corporation, and Taiho Pharmaceutical Co. have signed a three-party joint research agreement aimed at developing new cancer vaccines through the utilisation of whole-genome information.This Joint Research project will be carried out as part of the Japan Agency for Medical Research and Development (AMED)'s 'Action Plan for Whole-Genome Analysis for Cancer and Rare/Intractable Diseases', within the research initiative "Demonstration of the Clinical Utility of Cancer Whole-Genome Analysis and Research on Establishing Systems for Patient Benefit."JFCR, NEC, and Taiho will design and develop shared neoantigen cancer vaccines that target newly identified cancer-specifi...